S. 2706 117th Congress
DIVERSE Trials Act
Latest action, Aug 10, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
26 cosponsors
Sponsored by Robert Menendez (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
18 D · 7 R · 1 I
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
6 reports
6 reports
6 reports
JOHNSON & JOHNSON SERVICES, INC.
RAMPY NORTHRUP LLC
6 reports
JOHNSON & JOHNSON SERVICES, INC.
SPLITOAK STRATEGIES LLC
6 reports
5 reports
AMERICAN SOCIETY OF HEMATOLOGY
5 reports
5 reports
5 reports
5 reports
5 reports
All 25 of 36 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | 6 | $8.3M | Q4 2021 | Q3 2022 | yes | |
| DANA-FARBER CANCER INSTITUTE | 6 | $531K | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 6 | $6.7M | Q4 2021 | Q3 2022 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 6 | $10.6M | Q4 2021 | Q3 2022 | yes | |
| JOHNSON & JOHNSON SERVICES, INC. | RAMPY NORTHRUP LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| JOHNSON & JOHNSON SERVICES, INC. | SPLITOAK STRATEGIES LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | 6 | $2.1M | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | $42.9M | Q4 2021 | Q3 2022 | yes | |
| AMERICAN LUNG ASSOCIATION | 5 | $250K | Q4 2021 | Q3 2022 | yes | |
| AMERICAN SOCIETY OF HEMATOLOGY | 5 | $150K | Q4 2021 | Q3 2022 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 5 | $670K | Q4 2021 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 5 | $6.2M | Q4 2021 | Q3 2022 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 5 | $875K | Q4 2021 | Q3 2022 | yes | |
| GENENTECH INC | 5 | $10.3M | Q4 2021 | Q3 2022 | yes | |
| MUSCULAR DYSTROPHY ASSOCIATION, INC. | 5 | $820K | Q4 2021 | Q3 2022 | yes | |
| NATIONAL HEALTH COUNCIL | 5 | $125K | Q4 2021 | Q3 2022 | yes | |
| SUSAN G. KOMEN | ARTEMIS POLICY GROUP LLC | 5 | $208K | Q4 2021 | Q3 2022 | yes |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 5 | $320K | Q4 2021 | Q3 2022 | yes | |
| ALZHEIMER'S ASSOCIATION | 4 | $2.9M | Q1 2022 | Q3 2022 | yes | |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 4 | $1.8M | Q1 2022 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | RAMPY NORTHRUP LLC | 4 | $0 | Q1 2022 | Q3 2022 | — |
| BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | KOUNTOUPES DENHAM CARR & REID, LLC | 4 | $200K | Q1 2022 | Q3 2022 | yes |
| EMD SERONO INC | 4 | $2.2M | Q1 2022 | Q3 2022 | yes | |
| MERCK & CO. INC. | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| NATIONAL KIDNEY FOUNDATION | 4 | $460K | Q1 2022 | Q3 2022 | yes |